DDInter624 DDInter702
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoposide
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Etoposide
Efavirenz {u} (Compound) causes {v} (Side Effect) Necrolysis epidermal
Necrolysis epidermal {u} (Side Effect) is caused by {v} (Compound) Etoposide
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Podofilox
Podofilox {u} (Compound) resembles {v} (Compound) Etoposide
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etoposide
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) regulates {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Etoposide
Efavirenz {u} (Compound) causes {v} (Side Effect) Necrolysis epidermal
Necrolysis epidermal {u} (Side Effect) is caused by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Efavirenz {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etoposide
Efavirenz {u} (Compound) causes {v} (Side Effect) Skin exfoliation
Skin exfoliation {u} (Side Effect) is caused by {v} (Compound) Podofilox
Podofilox {u} (Compound) resembles {v} (Compound) Etoposide
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etoposide
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoposide (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Etoposide (Compound)
Efavirenz (Compound) causes Necrolysis epidermal (Side Effect) and Necrolysis epidermal (Side Effect) is caused by Etoposide (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Podofilox (Compound) and Podofilox (Compound) resembles Etoposide (Compound)
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) regulates CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Etoposide (Compound)
Efavirenz (Compound) causes Necrolysis epidermal (Side Effect) and Necrolysis epidermal (Side Effect) is caused by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Efavirenz (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Sparfloxacin (Compound) and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide
Efavirenz (Compound) causes Skin exfoliation (Side Effect) and Skin exfoliation (Side Effect) is caused by Podofilox (Compound) and Podofilox (Compound) resembles Etoposide (Compound)
Efavirenz (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide